Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.
NVO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Novo Nordisk A S with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Novo Nordisk A S ranked in the 68th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 152.5%. As for the metrics that stood out in our discounted cash flow analysis of Novo Nordisk A S, consider:
The company has produced more trailing twelve month cash flow than 99.55% of its sector Healthcare.
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 3.68% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 62.87% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
FMS, DVA, JAZZ, QDEL, and AMPH can be thought of as valuation peers to NVO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
DUBLIN, May 27, 2020 /PRNewswire/ -- The "Global Insulin Market - Focus on Insulin Delivery Devices [By Devices - Vials & Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors; By Region - North America (The US), Europe (The UK, Germany, France & Italy) and Asia Pacific (Japan,…
CBRE, leader in the real estate consultancy market, advised the relocation process for the pharmaceutical company Novo Nordisk, who leased an area of 580 sq m offices in the Tiriac Tower building, located in Victoriei Square. The transaction was signed in March, in full swing of the COVID-19 pandemic lockdown, thus confirming the continuity of […] The post Novo Nordisk leased the 9th floor in Tiriac Tower office building appeared first on Business Review .
DUBLIN--(BUSINESS WIRE)--The "Worldwide Diabetes Disposable Insulin Delivery Pen Market Prospect, Share, Development, Growth & Demand Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The Worldwide Diabetes Disposable Insulin Delivery Pen Market size is anticipated to exceed USD 14 billion by 2026. The objective of this market research report is to provide a comprehensive analysis of the fast-evolving, high-growth worldwide diabetes disposable insulin delivery pe